Etiologic field effect: Reappraisal of the field effect concept in cancer predisposition and progression

Modern Pathology

Volumn 28, Issue 1, 2015, Pages 14-29

  Lochhead, Paul ^a   Chan, Andrew T ^b,c   Nishihara, Reiko ^c,d   Fuchs, Charles S ^c   Beck, Andrew H ^c   Giovannucci, Edward ^c,d   Ogino, Shuji ^c,d,e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; ENVIRONMENTAL EXPOSURE; EPIGENETICS; ETIOLOGIC FIELD EFFECT; GENOMICS; METABOLOMICS; PROTEOMICS; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE COURSE; HUMAN; NEOPLASMS; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS;

EID: 84920643243     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.81     Document Type: Article

References (245)

1. Marusyk A, Almendro V, Polyak K. Intra-tumor heterogeneity: a looking glass for cancer. Nat Rev Cancer 2012;12:323-334.
2. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010;28: 2777-2783.
3. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-719.
4. Tjalsma H, Boleij A, Marchesi JR, et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012;10: 575-582.
5. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11:726-734.
6. Schottenfeld D, Beebe-Dimmer JL, Buffler PA, et al. Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors. Annu Rev Public Health 2013; 34:97-117.
7. Topalian SL,Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011;29: 4828-4836.
8. Weitzel JN, Blazer KR, Macdonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011;61:327-359.
9. Myers MB, Wang Y, McKim KL, et al. Hotspot oncomutations: implications for personalized cancer treatment. Expert Rev Mol Diagn 2012;12:603-620.
10. Sethi S, Ali S, Phillip PA, et al. Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci 2013;14:14771-14784.
11. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-968.
12. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 2009;69:5269-5284.
13. Gazdar AF, Minna JD. Multifocal lung cancers-clonality vs field cancerization and does it matter? J Natl Cancer Inst 2009;101:541-543.
14. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst 2005;97:1317-1319.
15. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007;40:142-150.
16. Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.
17. Chai H, Brown RE. Field effect in cancer-an update. Ann Clin Lab Sci 2009;39:331-337.
18. Ramachandran K, Singal R. DNA methylation and field cancerization. Epigenomics 2012;4:243-245.
19. Dakubo GD (ed). Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers: Hauppauge, NY, 2011.
20. Stearman RS, Dwyer-Nield L, Grady MC, et al. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res 2008;68:34-43.
21. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010;9:3256-3276.
22. Ge L, MengW, Zhou H, et al. Could stroma contribute to field cancerization? Med Hypotheses 2010;75: 26-31.
23. Hu B, Castillo E, Harewood L, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012;149: 1207-1220.
24. Vanharanta S, Massague J. Field cancerization: something new under the sun. Cell 2012;149:1179-1181.
25. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011;223:162-176.
26. Palmqvist R, Wikberg ML, Ling A, et al. The association of immune cell infiltration and prognosis in colorectal cancer. Curr Colorectal Cancer Rep 2013;9:372-379.
27. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 2014;232:199-209.
28. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15: 6412-6420.
29. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer and prognosis: cohort study and literature review. J Pathol 2010;222:350-366.
30. Dahlin AM, Henriksson ML, Van Guelpen B, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011;24:671-682.
31. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
32. Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a m1 or m2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PloS One 2012;7:e47045.
33. Thomas D. Gene-environment-wide association studies: emerging approaches. Nat Rev Genet 2010;11: 259-272.
34. Ballard-Barbash R, Friedenreich CM, Courneya KS, et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:815-840.
35. Vrieling A, Kampman E. The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am J Clin Nutr 2010;92:471-490.
36. Braakhuis BJM, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-1730.
37. Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 2009;118:229-239.
38. Franklin WA, Gazdar AF, Haney J, et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997;100:2133-2137.
39. Prevo LJ, Sanchez CA, Galipeau PC, et al. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-4787.
40. Rosenthal AN, Ryan A, Hopster D, et al. Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. Int J Cancer 2002;99:549-554.
41. Chu TY, Shen CY, Lee HS, et al. Monoclonality and surface lesion-specific microsatellite alterations in premalignant and malignant neoplasia of uterine cervix: a local field effect of genomic instability and clonal evolution. Genes Chromosomes Cancer 1999;24:127-134.
42. Heaphy CM, Bisoffi M, Fordyce CA, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2006;119:108-116.
43. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835-5841.
44. Henson DE, Schwartz AM, Nsouli H, et al. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study. Arch Pathol Lab Med 2009;133:67-71.
45. Davidson DD, Cheng L. 'Field cancerization' in the urothelium of the bladder. Anal Quant Cytol Histol 2006;28:337-338.
46. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-1338.
47. Issa JP, Ahuja N, Toyota M, et al. Accelerated agerelated CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-3577.
48. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60:5021-5026.
49. Habuchi T, Takahashi T, Kakinuma H, et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 2001;20:531-537.
50. Guo M, House MG, Hooker C, et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 2004;10: 5131-5136.
51. Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006;12:6626-6636.
52. Kamiyama H, Suzuki K, Maeda T, et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012;31: 5029-5037.
53. Asada K, Ando T, Niwa T, et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene 2013;32:2140-2149.
54. Shigaki H, Baba Y, Watanabe M, et al. LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann Surg Oncol 2012;19:4238-4243.
55. Subramaniam MM, Loh M, Chan JY, et al. The topography of DNA methylation in the non-neoplastic colonic mucosa surrounding colorectal cancers. Mol Carcinog 2013;53:98-108.
56. Kunte DP, Delacruz M, Wali RK, et al. Dysregulation of MicroRNAs in colonic field carcinogenesis: implications for screening. PloS One 2012;7:e45591.
57. Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology 2012;143:1442-60e1.
58. Hockel A, Dornhofer N. The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res. 2005;65:2997-3002.
59. Gustafson AM, Soldi R, Anderlind C, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra5.
60. Cheng L, Zhang S, Davidson DD, et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol 2009;5:843-857.
61. Steiling K, Ryan J, Brody JS, et al. The field of tissue injury in the lung and airway. Cancer Prev Res (Phila) 2008;1:396-403.
62. Kopelovich L, Henson DE, Gazdar AF, et al. Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect. Clin Cancer Res 1999;5:3899-3905.
63. Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-6519.
64. Cheng L, Davidson DD, Maclennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther 2010;10:865-880.
65. Ogino S, Brahmandam M, Kawasaki T, et al. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 2006;19:1083-1090.
66. Talbott VA, Yeo CJ, Brody JR, et al. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient. J Surg Res 2012;176: 154-158.
67. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009;137:1609-1620; e3.
68. Konishi K, Shen L, Jelinek J, et al. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila Pa) 2009;2:814-822.
69. Gonzalo V, Lozano JJ, Munoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PloS One 2010;5: e8777.
70. Bae JM, Cho NY, Kim TY, et al. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors. Dis Colon Rectum 2012;55:181-190.
71. Begg CB. A strategy for distinguishing optimal cancer subtypes. Int J Cancer 2011;129:931-937.
72. Arpino G, Weiss HL, Clark GM, et al. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005;23:4687-4694.
73. Kollias J, Pinder SE, Denley HE, et al. Phenotypic similarities in bilateral breast cancer. Breast Cancer Res Treat 2004;85:255-261.
74. Swain SM, Wilson JW, Mamounas EP, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-523.
75. Weitzel JN, Robson M, Pasini B, et al. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 2005;14:1534-1538.
76. Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004. Breast Cancer Res Treat 2010;120: 217-227.
77. Zauber P, Huang J, Sabbath-Solitare M, et al. Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other. J Mol Diagn 2013;15:652-660.
78. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011;476: 163-169.
79. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30:958-964.
80. Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst 2012;104: 1363-1372.
81. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
82. Galvan A, Ioannidis JP, Dragani TA. Beyond genomewide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010;26:132-141.
83. Slattery ML, Herrick J, Curtin K, et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res 2010;70:1479-1485.
84. Garcia-Albeniz X, Nan H, Valeri L, et al. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis 2013;34: 292-298.
85. Ogino S, Hazra A, Tranah GJ, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007;28:1985-1990.
86. Hawkins NJ, Lee JH, Wong JJ, et al. MGMT methylation is associated primarily with the germline C4T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol 2009;22:1588-1599.
87. Candiloro IL, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila Pa) 2009;2:862-867.
88. Leng S, Bernauer AM, Hong C, et al. The A/G allele of Rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res 2011;17:2014-2023.
89. Kristensen LS, Nielsen HM, Hager H, et al. Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer 2011;71:130-136.
90. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-367.
91. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
92. Herceg Z, Vaissiere T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics 2011;6:804-819.
93. Kitkumthorn N, Mutirangura A. Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenet 2012;2: 315-330.
94. Iwagami S, Baba Y, Watanabe M, et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol 2012;19:2726-2732.
95. Flanagan JM, Munoz-Alegre M, Henderson S, et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 2009;18:1332-1342.
96. Brennan K, Flanagan JM. Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res (Phila) 2012;5:1345-1357.
97. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004;1:e65.
98. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-139.
99. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-443.
100. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008;113: 1521-1526.
101. Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-1166.
102. Chen H, Taylor NP, Sotamaa KM, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 2007;120:1684-1688.
103. Raptis S, Mrkonjic M, Green RC, et al. MLH1-93G4A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst 2007;99:463-474.
104. Samowitz WS, Curtin K, Wolff RK, et al. The MLH1-93 G4A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosomes Cancer 2008;47:835-844.
105. Allan JM, Shorto J, Adlard J, et al. MLH1-93G4A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 2008;123: 2456-2459.
106. Campbell PT, Curtin K, Ulrich CM, et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut 2009;58:661-667.
107. Oyama K, Kawakami K, Maeda K, Ishiguro K, Watanabe G. The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res 2004;24:649-654.
108. Curtin K, Slattery ML, Ulrich CM, et al. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis 2007;28:1672-1679.
109. de Vogel S,Wouters KA, Gottschalk RW, et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:3086-3096.
110. Schernhammer ES, Giovannucci E, Kawasaki T, et al. Dietary folate, alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010; 59:794-799.
111. Hazra A, Fuchs CS, Kawasaki T, et al. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control 2010;21:331-345.
112. Van Guelpen B, Dahlin AM, Hultdin J, et al. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control 2010;21:557-566.
113. Curtin K, Samowitz WS, Ulrich CM, et al. Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer 2011;63:357-366.
114. Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PloS One 2011;6:e21102.
115. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000;92:1831-1836.
116. Satia JA, Keku T, Galanko JA, et al. Diet, lifestyle, and genomic instability in the north Carolina colon cancer study. Cancer Epidemiol Biomarkers Prev 2005;14:429-436.
117. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26:5713-5720.
118. Campbell PT, Jacobs ET, Ulrich CM, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 2010;102:391-400.
119. Kuchiba A, Morikawa T, Yamauchi M, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst 2012;104:415-420.
120. Sinicrope FA, Foster NR, Yoon HH, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol 2012;30: 406-412.
121. Hughes LA, Williamson EJ, van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. Int J Epidemiol 2012;41:1060-1072.
122. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006;98:1731-1738.
123. Poynter JN, Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009;18:2745-2750.
124. Rozek LS, Herron CM, Greenson JK, et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010;19:838-843.
125. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102: 1012-1022.
126. Curtin K, Samowitz WS, Wolff RK, et al. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer 2009;125:158-164.
127. Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 2013;178:84-100.
128. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
129. Kawaguchi T, Ando M, Kubo A, et al. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 2011;17: 39-45.
130. Martinez ME, Maltzman T, Marshall JR, et al. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999;59:5181-5185.
131. Baba Y, Huttenhower C, Nosho K, et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010;9:125.
132. Goel A, Xicola RM, Nguyen TP, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2010;138:1854-1862.
133. Antelo M, Balaguer F, Shia J, et al. A high degree of LINE-1 hypomethylation is a unique feature of earlyonset colorectal cancer. PloS One 2012;7:e45357.
134. Ogino S, Nishihara R, Lochhead P, et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 2013;105:130-140.
135. Ogino S, Nishihara R, Lochhead P, et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 2013;105:130-140.
136. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142.
137. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658.
138. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation status, and colorectal cancer survival. N Engl J Med 2012;367:1596-1606.
139. Pasche B. Aspirin-from prevention to targeted therapy. N Engl J Med 2012;367:1650-1651.
140. Kang GH, Lee S, Kim WH, et al. Epstein-barr viruspositive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002;160:787-794.
141. Chang MS, Uozaki H, Chong JM, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006;12:2995-3002.
142. Ryan JL, Jones RJ, Kenney SC, et al. Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infect Agent Cancer 2010;5:27.
143. Ding SZ, Goldberg JB, Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol 2010;6:851-862.
144. Peterson AJ, Menheniott TR, O'Connor L, et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology 2010;139:2005-2017.
145. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PloS One 2010;5:e9749.
146. Gao W, Kondo Y, Shen L, et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008; 29:1901-1910.
147. Vivekanandan P, Daniel HD, Kannangai R, Martinez-Murillo F, Torbenson M. Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol 2010;84:4321-4329.
148. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013;26:465-484.
149. Ogino S, Giovannucci E. Commentary: lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. In J Epidemiol 2012; 41:1072-1074.
150. Ogino S, King EE, Beck AH, et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol 2012;176:659-667.
151. Ogino S, Beck AH, King EE, et al. Ogino et al. respond to 'The 21st century epidemiologist'. Am J Epidemiol 2012;176:672-674.
152. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-628.
153. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int 2011;2011:902674.
154. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PloS One 2011;6:e18571.
155. Gehoff A, Basten O, Sprenger T, et al. Optimal lymph node harvest in rectal cancer (UICC Stages II and III) after preoperative 5-FU-based radiochemotherapy. acetone compression is a new and highly efficient method. Am J Surg Pathol 2012;36:202-213.
156. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012;1825:77-85.
157. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012;25:1055-1068.
158. Kanthan R, Senger JL, Kanthan SC. Molecular events in primary and metastatic colorectal carcinoma: a review. Pathol Res Int 2012;2012:597497.
159. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107: 1315-1329.
160. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012;18:6169-6177.
161. Galon J, Franck P, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
162. Spitz MR, Caporaso NE, Sellers TA. Integrative cancer epidemiology-the next generation. Cancer Discov 2012;2:1087-1090.
163. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013;26:825-834.
164. Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol 2013;31:876-885.
165. Weijenberg MP, Hughes LA, Bours MJ, et al. The mTOR pathway and the role of energy balance throughout life in colorectal cancer etiology and prognosis: unravelling mechanisms through a multidimensional molecular epidemiologic approach. Curr Nutr Rep 2013;2:19-26.
166. Alvarez MC, Santos JC, Maniezzo N, et al. MGMTand MLH1 methylation in Helicobacter pylori-infected children and adults. World J Gastroenterol 2013;19: 3043-3051.
167. Hagland HR, Berg M, Jolma IW, Carlsen A, Soreide K. Molecular pathways and cellular metabolism in colorectal cancer. Digestive Surg 2013;30:12-25.
168. Burnett-Hartman AN, Newcomb PA, Potter JD, et al. Genomic aberrations occuring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013;73:2863-2872.
169. Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013; 52:585-589.
170. Abbenhardt C, Poole EM, Kulmacz RJ, et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet 2013;4:140-149.
171. Hughes LA, Melotte V, de Schrijver J, et al. The CpG island methylator phenotype: what's in a name? Cancer Res 2013;73:5858-5868.
172. Amirian ES, Petrosino JF, Ajami NJ, et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer 2013;8:42.
173. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013;109:1004-1012.
174. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA 2013;310: 2401-2402.
175. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 2013;22:2303-2311.
176. Zhu Y, Yang SR, Wang PP, et al. Influence of prediagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer 2014;110:1359-1366.
177. Larsson E, Tremaroli V, Lee YS, et al. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut 2012;61:1124-1131.
178. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-854.
179. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell 2011;144:986-998.
180. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet 2012;21:3073-3082.
181. Shenker NS, Polidoro S, van Veldhoven K, et al. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet 2013;22: 843-851.
182. Toyomura K, Yamaguchi K, Kawamoto H, et al. Relation of cigarette smoking and alcohol use to colorectal adenomas by subsite: the self-defense forces health study. Cancer Sci 2004;95:72-76.
183. Buda A, De Bona M, Dotti I, et al. Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy. Clin Transl Gasntroenterol 2012;3:e6.
184. Yamamoto E, Suzuki H, Yamano HO, et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG Island methylator phenotype. Am J Pathol 2012;181:1847-1861.
185. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013;5:676-713.
186. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-16385.
187. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012;21: 1792-1798.
188. Gavin P, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18:6531-6541.
189. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8: 686-700.
190. Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010;16: 1845-1855.
191. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high,-low, and-negative colorectal cancers based on protein marker expression and molecular features. J Pathol 2011;225:336-343.
192. Ang PW, Loh M, Liem N, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010;10:227.
193. Wu C, Bekaii-Saab T. CpG island methylation, microsatellite instability, and BRAF mutations and their clinical application in the treatment of colon cancer. Chemother Res Prac 2012;2012:359041.
194. Beggs AD, Jones A, El-Bahwary M, et al. Wholegenome methylation analysis of benign and malignant colorectal tumours. J Pathol 2013;229:697-704.
195. Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology 2012;61:777-787.
196. Leggett BA, Worthley DL. Synchronous colorectal cancer: not just bad luck? Gastroenterology 2009;137: 1559-1562.
197. Naguib A, Mitrou PN, Gay LJ, et al. Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer 2010;10:99.
198. Weijenberg MP, Aardening PW, de Kok TM, de Goeij AF, van den Brandt PA. Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study. Mutat Res 2008;652:54-64.
199. Diergaarde B, Vrieling A, van Kraats AA, et al. Cigarette smoking and genetic alterations in sporadic colon carcinomas. Carcinogenesis 2003;24:565-571.
200. Slattery ML, Anderson K, Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001;483:73-81.
201. Samadder NJ, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. Am J Gastroenterol 2012;107:782-789.
202. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009;2:310-321.
203. Benamouzig R, Uzzan B, Deyra J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 2012;61:255-261.
204. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013;309:2563-2571.
205. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-1601.
206. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518-527.
207. Schaal C, Chellappan SP. Nicotine-mediated cell proliferation and tumor progression in smokingrelated cancers. Mol Cancer Res 2014;12:14-23.
208. Yoshino I, Kometani T, Shoji F, et al. Induction of epithelial-mesenchymal transition-related genes by Benzo[a]Pyrene in lung cancer cells. Cancer 2007;110:369-374.
209. Di Cello F, Flowers VL, Li HL, et al. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer 12:90 2013.
210. Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer 2011;11:512-522.
211. Wu JM, Beck AH, Pate LL, et al. Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res 2011;17:437-446.
212. Straussman R, Morikawa T, Shee K, et al. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature 2012; 487:500-504.
213. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde JH. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep 2013;1: 166-183.
214. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012;61:794-497.
215. Leedham S, Tomlinson I. The continuum model of selection in human tumors: general paradigm or niche product? Cancer Res 2012;72:3131-3134.
216. Stead M, Caswell S, Craigie AM, Eadie D, Anderson AS. Understanding the potential and challenges of adenoma treatment as a prevention opportunity: insights from the BeWEL formative study. Preven Med 2012;54:97-103.
217. Caswell S, Anderson AS, Steele RJ. Bowel health to better health: a minimal contact lifestyle intervention for people at increased risk of colorectal cancer. Br J Nutr 2009;102:1541-1546.
218. Kim DH, Smith-Warner SA, Spiegelman D, et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control 2010;21:1919-1930.
219. Lee JE, Willett WC, Fuchs CS, et al. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr 2011;93:817-825.
220. McGlynn AP, Wasson GR, O'Reilly SL, et al. Low colonocyte folate is associated with uracil misincorporation and global DNA hypomethylation in human colorectum. J Nutr 2013;143:27-33.
221. Michor F, Liphardt J, Ferrari M, Widom J. What does physics have to do with cancer? Nat Rev Cancer 2011;11:657-670.
222. Shanmuganathan R, Nazeema Banu B, Amirthalingam L, et al. Conventional and nanotechniques for DNA methylation profiling. J Mol Diagn 2013;15: 17-26.
223. Wild CP, Scalbert A, Herceg Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ Mol Mutagen 2013;54:480-499.
224. Silviera ML, Smith BP, Powell J, Sapienza C. Epigenetic differences in normal colon mucosa of cancer patients suggest altered dietary metabolic pathways. Cancer Prev Res (Phila) 2012;5:374-384.
225. Yang Q, Dong Y, Wu W, et al. Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation. Nat Commun 2012; 3:1206.
226. Damania D, Roy HK, Subramanian H, et al. Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. Cancer Res 2012;72:2720-2727.
227. Backman V, Roy HK. Light-scattering technologies for field carcinogenesis detection: a modality for endoscopic prescreening. Gastroenterology 2011;140: 35-41.
228. Roberts NJ, Vogelstein JT, Parmigiani G, et al. The predictive capacity of personal genome sequencing. Sci Transl Med 2012;4:133ra58.
229. Snyder M, Weissman S, Gerstein M. Personal phenotypes to go with personal genomes. Mol Systems Biol 2009;5:273.
230. Rivera CM, Ren B. Mapping human epigenomes. Cell 2013;155:39-55.
231. Monick MM, Beach SR, Plume J, et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am J Med Genet B Neuropsychiatr Genet 2012;159B: 141-151.
232. Zhang FF, Cardarelli R, Carroll J, et al. Physical activity and global genomic DNA methylation in a cancer-free population. Epigenetics 2011;6:293-299.
233. Langevin SM, Houseman EA, Christensen BC, et al. The influence of aging, environmental exposures and local sequence features on the variation of DNA methylation in blood. Epigenetics 2011;6: 908-919.
234. Brody JS. Transcriptome alterations induced by cigarette smoke. Int J Cancer 2012;131:2754-2762.
235. De Coster S, van Leeuwen DM, Jennen DG, et al. Gender-specific transcriptomic response to environmental exposure in Flemish adults. Environ Mol Mutagen 2013;54:574-588.
236. Beineke P, Fitch K, Tao H, et al. A whole blood gene expression-based signature for smoking status. BMC Med Genomics 2012;5:58.
237. Pagmantidis V, Meplan C, van Schothorst EM, Keijer J, Hesketh JE. Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes. Am J Clin Nutr 2008;87: 181-189.
238. Rappaport SM. Biomarkers intersect with the exposome. Biomarkers 2012;17:483-489.
239. Gonzalez LC. Protein microarrays, biosensors, and cellbased methods for secretome-wide extracellular proteinprotein interaction mapping. Methods 2012;57:448-458.
240. Roy HK, Gomes A, Turzhitsky V, et al. Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk. Gastroenterology 2008;135:1069-1078.
241. Roy HK, Turzhitsky V, Kim Y, et al. Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res 2009;69:4476-4483.
242. Shaheen NJ. Editorial: what is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol 2014;109:345-347.
243. Brandstedt J, Wangefjord S, Nodin B, et al. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatelliteinstability. BMC Cancer 2014;14:371.
244. Coppede F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol 2014 (e-pub ahead of print).
245. Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 2014;20:6055-6072.